Using sulforaphane from broccoli to prevent malignant mesothelioma
PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate BiomarkersTask Order Title: Sulforaphane for the Prevention of Malignant Mesothelioma
This study is looking at whether a natural compound from broccoli called sulforaphane can help prevent malignant mesothelioma, a serious cancer often caused by asbestos, especially in people who are at higher risk for cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10836806 on NIH RePORTER |
What this research studies
This research investigates the potential of sulforaphane, a compound derived from broccoli, as a preventive treatment for malignant mesothelioma, a highly aggressive cancer linked to asbestos exposure. The study focuses on individuals at high risk, particularly those with a genetic predisposition to cancer, and aims to identify effective biomarkers for monitoring treatment efficacy. By targeting inflammatory mediators involved in cancer development, the research seeks to intercept tumor progression before it becomes malignant. Participants may receive sulforaphane over an extended period to assess its long-term safety and effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a history of asbestos exposure or those with a germline mutation of BAP1, which increases their risk for mesothelioma.
Not a fit: Patients who do not have a history of asbestos exposure or genetic predisposition to mesothelioma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a preventive strategy for individuals at high risk of developing malignant mesothelioma, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in using sulforaphane as a cancer preventive agent, indicating potential for success in this novel application.
Where this research is happening
Philadelphia, United States
- Research Inst of Fox Chase Can Ctr — Philadelphia, United States (Active)
Researchers
- Principal investigator: Testa, Joseph — Research Inst of Fox Chase Can Ctr
- Study coordinator: Testa, Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.